Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

L.J. Schouten; P.A. van den Brandt; the Collaborative Group on Epidemiological Studies of Ovarian Cancer; S. M. Gapstur

doi:10.1016/S0140-6736(14)61687-1

Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

L.J. Schouten, P.A. van den Brandt, the Collaborative Group on Epidemiological Studies of Ovarian Cancer, S. M. Gapstur^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with

Original language	English
Pages (from-to)	1835-1842
Journal	Lancet
Volume	385
Issue number	9980
DOIs	https://doi.org/10.1016/S0140-6736(14)61687-1
Publication status	Published - 1 Jan 2015

Access to Document

10.1016/S0140-6736(14)61687-1Licence: CC BY

Cite this

@article{7319ab873f0b49b48dfc3959cb6c55c6,

title = "Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies",

abstract = "Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with ",

author = "L.J. Schouten and {van den Brandt}, P.A. and {Collaborative Group on Epidemiological Studies of Ovarian Cancer}, the and Gapstur, {S. M.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/S0140-6736(14)61687-1",

language = "English",

volume = "385",

pages = "1835--1842",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Science",

number = "9980",

}

Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. / Schouten, L.J.; van den Brandt, P.A.; Collaborative Group on Epidemiological Studies of Ovarian Cancer, the et al.
In: Lancet, Vol. 385, No. 9980, 01.01.2015, p. 1835-1842.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

AU - Schouten, L.J.

AU - van den Brandt, P.A.

AU - Collaborative Group on Epidemiological Studies of Ovarian Cancer, the

AU - Gapstur, S. M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with

AB - Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with

U2 - 10.1016/S0140-6736(14)61687-1

DO - 10.1016/S0140-6736(14)61687-1

M3 - Article

SN - 0140-6736

VL - 385

SP - 1835

EP - 1842

JO - Lancet

JF - Lancet

IS - 9980

ER -